Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Celsion Corporation
The oncologic drugs advisory committee’s upcoming reviews are moving beyond the PD-1/PDL-1 inhibitor class – and to a very different type of sponsor.
Endo enters into an agreement with the subsidiaries of Strides Pharma to sell its manufacturing site in Chestnut Ridge, New York. Meanwhile, the company sees a double-digit drop in its generics business. Furthermore, Endo executes settlement resolving all opioid-related claims in Tennessee.
Endo’s Par looks set to provide much needed supply in the US market for varenicline tablets, after originator Pfizer ran into supply and distribution problems due to the presence of a nitrosamine for its Chantix original.
Federal Circuit panel to reconsider whether Teva induced infringement of GSK Coreg patent despite label carve-out. Biologics and biosimilars could be particularly hurt if ruling stands given FDA’s recent guidance requiring reference to branded product.
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
- Egen, Inc.
- Expression Genetics